Articles tagged with Proteinuria
Researchers identified C-C chemokine ligand 5 (CCL5) as a key player in kidney injury and repair, with the molecule behaving both protectively and harmfully. The study suggests future drugs could target only its damaging effects, paving the way for more precise treatments for chronic kidney disease.
Elevated cdc42 activity is a critical initiation event leading to proteinuria in nephrotic syndrome. Suppression of cdc42 activity could be a promising therapy.
A new study suggests that paricalcitol may help manage chronic kidney disease (CKD) in dogs by reducing renal secondary hyperparathyroidism and proteinuria. The treatment showed promise in stabilizing proteinuria, but raised questions about potential long-term effects on CKD progression.
Research finds that Streptococcus mutans's collagen-binding protein may induce hematuria and IgA deposition in kidney disease, suggesting a potential pathogenic role. The study suggests a link between oral pathogens and renal lesions.
Researchers discovered that patients with FSGS who received sparsentan treatment experienced improved kidney function and reduced proteinuria, a key indicator of kidney damage. The study suggests sparsentan may be a potential new treatment option for the disorder, offering hope for patients affected by FSGS.
In a cohort study of 2,055 patients with glomerular diseases, COVID-19 vaccination did not worsen kidney damage or affect proteinuria. The data support vaccination for COVID-19 in patients with glomerular disease.
A study from Aarhus University reveals that PCSK9 regulates a receptor in the kidneys controlling protein excretion, leading to potential new treatment strategies for patients with kidney overloads. The researchers hope to further investigate the use of PCSK9 inhibitors in treating kidney diseases.
Researchers found that acute kidney injury does not predict worsening of kidney function trajectory in patients with CKD, suggesting that pre-existing kidney disease may be a major contributor. The study recommends focusing on flattening the eGFR slope and treating proteinuria to slow CKD progression.
The 2017 American Academy of Pediatrics guideline shows higher levels of proteinuria in children with hypertensive range blood pressure. Clinicians should re-calculate BP percentiles using the new guidelines to accurately diagnose and treat hypertension in pediatric chronic kidney disease.
Patients with primary glomerular diseases have a significantly higher risk of cardiovascular events, including coronary artery disease and stroke. The study found that inclusion of kidney-specific risk factors improved the prediction of cardiovascular events.
Researchers have identified the alternative complement pathway as a key driver of IgA nephropathy, a chronic kidney disease. Iptacopan, an oral inhibitor of Factor B, has been shown to significantly reduce proteinuria and stabilize renal function in patients with IgAN, offering a new therapeutic approach.
The ACCOLADE study found that avacopan slowed C3 glomerulopathy progression by 20.6% in the placebo group but improved by 0.2% in the avacopan group, with patients with low eGFR benefiting from therapy. Avacopan also reduced proteinuria and increased eGFR in both groups.
Researchers from Kanazawa University found that skipping breakfast and late dinner are associated with an increased risk of proteinuria, a key prognostic factor of CKD. Unhealthy dietary habits, including quick eating, were linked to the development of proteinuria despite no changes in body weight.
A new analysis by Children's National Hospital researchers found that reducing proteinuria in patients with FSGS significantly slows declines in kidney function and extends time before kidneys fail. The study showed that even modest reductions in proteinuria have a positive impact on kidney health.
A multicenter trial found that linagliptin reduced albuminuria but had no significant effect on eGFR or cardiovascular risk in patients with diabetes. The study also suggested that stratifying patients with nephrotic-range proteinuria could lead to better outcomes.
Researchers identified several potential therapeutic targets for Alport syndrome, including bardoxolone and anti-miRNA21. The disease is characterized by progressive kidney damage and proteinuria, and current treatments are primarily aimed at slowing disease progression rather than halting it.
A study found that the blood pressure-lowering medication ramipril reduced protein excretion in children with chronic kidney disease, which was linked to a lower risk of disease progression. The findings suggest that proteinuria lowering is an important target in managing pediatric CKD.
A high-fat diet fed to pregnant rats for 20 days resulted in preeclampsia-like syndromes and increased expression of metabotropic glutamate receptor 1 in the rat hippocampus. This finding suggests that controlling fat intake may be crucial in preventing pregnancy-induced eclampsia.
A new study by the American Society of Nephrology found that ramipril lowers the risk of kidney disease progression in all weight groups, but shows a significant reduction in obese patients. Obese patients with kidney disease progress more quickly towards renal failure compared to non-obese patients.
Researchers have identified a protein that compromises kidney function and cause nephrotic syndrome. A naturally occurring precursor to an acid in the body may offer a new potential treatment for some forms of the condition.
Researchers analyzed over 920,000 adults and found that a faster kidney filtration rate and higher protein levels in the urine increased the risk of acute kidney injury. The study suggests using both kidney function data and proteinuria to identify individuals at risk.
A study reveals that HIV-infected injection drug users are more likely to develop proteinuria, a marker of kidney disease, which can lead to kidney failure. Clinicians should aggressively screen this population for proteinuria and consider them candidates for medical treatments that protect the heart and kidneys.
A morning urine test is superior for detecting declining kidney performance in patients with diabetic kidney disease. The albumin:creatinine ratio from a first morning urine sample predicts worsening kidney problems more accurately than other methods.
A study found that bevacizumab increases the risk of severe urinary protein loss by more than four-fold in patients, highlighting the need for monitoring kidney health when prescribing this cancer drug. Patients with kidney cancer or receiving high doses of bevacizumab are at greatest risk.
Avosentan significantly reduces urinary protein loss in people with type 2 diabetes and kidney disease, but also causes serious side effects such as pulmonary edema and congestive heart failure. Lower doses of avosentan may have a more favorable risk/benefit ratio for patients.
Patients with reduced kidney function and high proteinuria at increased risk of death, heart attacks, or progression to kidney failure. The study suggests that future guidelines for chronic kidney disease classification should incorporate information on proteinuria levels.
Researchers have identified multiple chromosomal regions associated with genes influencing variation in proteinuria, particularly in the setting of diabetes or hypertension. The study's findings suggest that genetic variation likely accounts for part of the increased risk of kidney disease in American Indians.
A systematic review of 16 studies found proteinuria to be a poor predictor of adverse outcomes. However, a slight association was observed with stillbirths at a proteinuria level of 5g in 24 hours.
A study found that proteinuria levels are higher in children with low glomerular filtration rates and non-Caucasian race, suggesting genetic or environmental factors. The study also found that patients taking renin-angiotensin system antagonizing drugs had lower levels of proteinuria compared to those not on these medications.
A study found that taking a much higher dose of candesartan cilexetil effectively lowers protein excretion in the urine of patients with kidney disease. The drug may help prevent end-stage kidney disease and save lives by reducing proteinuria.
A systematic review and meta-analysis found a strong association between proteinuria and the risk of coronary heart disease. The study suggests that markers of kidney dysfunction may be used as indicators for coronary heart disease risk, highlighting the importance of monitoring kidney function in patients with cardiovascular disease.
A new study found that combining two commonly used blood pressure medications, ACE inhibitors and ARBs, reduces urine protein levels more than taking either medication alone. However, it also causes more kidney damage and a higher risk of death among high-risk patients.
A newly identified molecular pathway involving the urokinase receptor (uPAR) appears to play a crucial role in the breakdown of kidney filtration structures, leading to proteinuria. The research suggests that targeting this pathway with antibodies or small molecule compounds could prevent or decrease proteinuria in animals.
The American College of Physicians has released comprehensive guidelines for diagnosing and treating stable chronic obstructive pulmonary disease. A new study also found that a nutrient supplement can reduce the need for steroids in patients with stubborn ulcerative colitis. Additionally, an atypical antipsychotic drug has been shown t...
Massachusetts General Hospital researchers discovered that a specific enzyme called cathepsin L causes proteinuria by breaking down dynamin, leading to podocyte damage. Altered forms of dynamin may be able to block this process and restore kidney function.
Researchers have discovered that combining two blood pressure-lowering drugs with enzyme replacement therapy can slow the progression of kidney disease in patients with severe Fabry disease. The study found significant reductions in proteinuria and minimal decline in kidney function after an average of two and a half years' treatment.
A new algorithm calculates the ratio of three specific proteins in urine and blood to identify severe preeclampsia with high sensitivity and specificity. This approach may provide a more accurate diagnosis than current tests, which can be confusing and lead to premature birth.
The new report clarifies how to monitor and treat pregnant women with hypertension before and during pregnancy. It highlights the importance of differentiating between hypertension and preeclampsia, a condition that affects the placenta, kidney, liver, and brain, and can lead to severe complications for both mother and child.